Vinti Agarwal

Dr. Vinti Agarwal


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMChris Macraild
Chris Macraild
MRMuzaffar Ur Rehman
Muzaffar Ur Rehman
FAFaheem
Faheem
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
ISIan K. Styles
Ian K. Styles
SVSeshadri S Vasan
Seshadri S Vasan
SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14,000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA-approved molecules with established safety profiles that have plausible mechanisms for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising drug candidates that can be repurposed for the safe, efficacious, and cost-effective treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx that was also developed to enable the scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.

18 November 2022 in Data
Verified
Journal Article
Open access
PDF file
HJHardik Jain
Hardik Jain
VAVinti Agarwal
Vinti Agarwal
CBChaarvi Bansal
Chaarvi Bansal
Anupama KumarAnupama Kumar
Anupama Kumar
FAFaheem
Faheem
SVSeshadri S Vasan
Seshadri S Vasan
Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.

20 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
CMChris Macraild
Chris Macraild
MRMuzaffar Ur Rehman
Muzaffar Ur Rehman
FFFaheem Faheem
Faheem Faheem
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
ISIan K. Styles
Ian K. Styles
SVSeshadri S Vasan
Seshadri S Vasan
SARS-CoV-2, is the cause of the COVID-19 pandemic which has claimed more than six million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA approved molecules with established safety profiles that have a plausible mechanism for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising repurposable drug candidates that are safe, efficacious, and cost-effective for the treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx, https://www.covirx.org/) that was also developed to enable scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.

21 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
HJHardik Jain
Hardik Jain
VAVinti Agarwal
Vinti Agarwal
CBChaarvi Bansal
Chaarvi Bansal
AKAnupama Kumar
Anupama Kumar
FFFaheem Faheem
Faheem Faheem
SVSeshadri S Vasan
Seshadri S Vasan
Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to quickly get safe, effective, and affordable COVID-19 treatment is to repurpose drugs that are already approved for other diseases as adjuvants along with the ongoing vaccine regime. The process of developing an accurate and standardized drug repurposing dataset requires a considerable level of resources and expertise due to the commercial availability of an extensive array of drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx platform. CoviRx is a user-friendly interface that provides access to the data, which is manually curated for COVID-19 drug repurposing data. Through CoviRx, the data curated has been made open-source to help advance drug repurposing research. CoviRx also encourages users to submit their findings after thoroughly validating the data, followed by merging it by enforcing uniformity and integ-rity-preserving constraints. This article discusses the various features of CoviRx and its design principles. CoviRx has been designed so that its functionality is independent of the data it dis-plays. Thus, in the future, this platform can be extended to include any other disease X beyond COVID-19. CoviRx can be accessed at www.covirx.org.

21 July 2025 in arXiv
Verified
Preprint
Open access
PDF file
AGApoorva Gulati
Apoorva Gulati
RKRajesh Kumar
Rajesh Kumar
VAVinti Agarwal
Vinti Agarwal
ASAditya Sharma
Aditya Sharma
Large Language Models (LLMs) have made it easier to create realistic fake profiles on platforms like LinkedIn. This poses a significant risk for text-based fake profile detectors. In this study, we evaluate the robustness of existing detectors against LLM-generated profiles. While highly effective in detecting manually created fake profiles (False Accept Rate: 6-7%), the existing detectors fail to identify GPT-generated profiles (False Accept Rate: 42-52%). We propose GPT-assisted adversarial training as a countermeasure, restoring the False Accept Rate to between 1-7% without impacting the False Reject Rates (0.5-2%). Ablation studies revealed that detectors trained on combined numerical and textual embeddings exhibit the highest robustness, followed by those using numerical-only embeddings, and lastly those using textual-only embeddings. Complementary analysis on the ability of prompt-based GPT-4Turbo and human evaluators affirms the need for robust automated detectors such as the one proposed in this study.

22 September 2025
Verified
Book Chapter
Closed access
PDF file
SPShashwath Punneshetty
Shashwath Punneshetty
DIDhyey Italiya
Dhyey Italiya
VAVinti Agarwal
Vinti Agarwal
CMChandresh Maurya
Chandresh Maurya
AAAmit Agrawal
Amit Agrawal